EPO Knocks Down Trio of Geron Patent Claims

Law360, New York (June 14, 2006, 12:00 AM EDT) -- In another blow to Geron Corp., the European Patent Office has ruled in favor of Danish pharmaceutical giant Pharmexa A/S and invalidated three claims of the U.S. biotechnology company’s European patent related to telomerase-targeted cancer vaccines.

On Wednesday, Pharmexa announced that the EPO had rejected a trio of Geron’s patent claims involving peptide vaccines against telomerase, an enzyme that adds specific DNA sequence repeats to the ends of DNA strands.

"It was a clear decision, solidly based on the arguments Pharmexa has presented,” said Jakob Schmidt,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.